Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Crestor, Rosuvastatin AND Diabetes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Crestor, Rosuvastatin AND Diabetes. Displaying page 1 of 1.
    EudraCT Number: 2005-002510-38 Sponsor Protocol Number: D3569C00007 Start Date*: 2005-12-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excreti...
    Medical condition: Male and female patients aged >= 18 and <=70 years with Type 1 or 2 diabetes, moderate proteinuria (baseline urinary protein/creatinine ratio >=500 mg/g and <=5000 mg/g), mild hypercholesterolaemia...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002333-11 Sponsor Protocol Number: R727-CL-1118 Start Date*: 2013-04-12
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin versus Ezetimibe Added-on to Rosuvastatin versus Rosuvastatin Dose Increase in Patients Who are Not C...
    Medical condition: Patients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with rosuvastatin (10mg or 20mg) with or witho...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002777-68 Sponsor Protocol Number: ROV-01 Start Date*: 2006-07-12
    Sponsor Name:Cardiff and Vale NHS Trust
    Full Title: The effects of rosuvastatin therapy on glucose metabolism in non-diabetic renal transplant recipients with a focus on insulin sensitivity and pancreatic beta islet cell function
    Medical condition: New-onset diabetes after transplantation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063634 Post transplant diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004953-14 Sponsor Protocol Number: 0653-139 Start Date*: 2009-01-16
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate and Compare the Efficacy and Safety of Ezetimibe 10 mg Added on to Rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg Versus Up-Titration...
    Medical condition: hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004094-28 Sponsor Protocol Number: D3560L00030 Start Date*: 2005-05-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL...
    Medical condition: healthy subjects without prior history of MI, stroke or arterial revascularization who, on initial screening, are found to have LDL.C levels below 130 mg/dL (3.36 mmol/L) and CRP levels equal to or...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) DE (Prematurely Ended) GB (Completed) EE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003837-13 Sponsor Protocol Number: ROPPET-NAF Start Date*: 2020-04-20
    Sponsor Name:Centro Hospitalar e Universitário de Coimbra, E.P.E.
    Full Title: Rosuvastatin effect on atherosclerotic plaque metabolism ¿ a subclinical atherosclerosis imaging study with 18F-NaF PET-CT
    Medical condition: Atherosclerosis, namely in the aorta, carotid and coronary arteries
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002616-96 Sponsor Protocol Number: D3561C00087 Start Date*: 2006-08-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12-week, double-blind, randomiz...
    Medical condition: Heterozygous familial hypercholesterolemia (HeFH) is a frequent, inherited disorder of lipoprotein metabolism caused by mutations in the LDL receptor gene. The risk of CHD is approximately 50% by 5...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006937-28 Sponsor Protocol Number: OPHT-040908 Start Date*: 2009-03-30
    Sponsor Name:Universitätsklinik für Klinische Pharmakologie
    Full Title: Effect of Rosuvastatin on endothelial function in patients with diabetes and glaucoma
    Medical condition: volunteers with Diabetes type I or II and volunteers with Glaucoma are included Glaucoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012602 Diabetes mellitus (incl subtypes) HLT
    9.1 10018305 Glaucomas (excl congenital) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000486-37 Sponsor Protocol Number: 2013-000486-37 Start Date*: 2013-07-16
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults.
    Medical condition: HIV AND HYPERCHOLESTEROLAEMIA
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001493-91 Sponsor Protocol Number: 20130630 Start Date*: 2007-08-22
    Sponsor Name:Population Health Research Institute, McMaster University/Hamilton Health Sciences
    Full Title: Heart Outcomes Prevention Evaluation (HOPE-3)
    Medical condition: Healthy individuals at average risk, without a clear indication or contraindication to lipid lowering or blood pressure lowering with any of the study drugs. Women aged >60 years of age with at lea...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10022891 - Investigations 10053046 Cardiovascular evaluation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Ongoing) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002550-56 Sponsor Protocol Number: D6160C00003 Start Date*: 2005-03-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effec...
    Medical condition: Men or women diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents, and with diabetic dyslipidaemia; ie low HD...
    Disease: Version SOC Term Classification Code Term Level
    7 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-007689-52 Sponsor Protocol Number: 0653A-133 Start Date*: 2009-05-27
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg...
    Medical condition: Lipids not at goal in diabetic patients with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) DE (Completed) LV (Completed) AT (Completed) EE (Completed) IT (Completed) PT (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002549-11 Sponsor Protocol Number: D6160C00038 Start Date*: 2005-06-20
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar 1 mg in patients with Type 2 Diabetes.
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) HU (Completed) CZ (Completed) SK (Completed) EE (Completed) LV (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006219-56 Sponsor Protocol Number: 121-00 Start Date*: 2007-03-08
    Sponsor Name:Merck & Co Inc.,
    Full Title: A multicentre, double-blind, randomised, parallel-group study to evaluate the efficacy, safety and tolerability of ezetimibe/simvastatin 10/40mg, atorvastatin 40mg, and rosuvastatin 10mg to achieve...
    Medical condition: Primary Hypercholesterolaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002344-24 Sponsor Protocol Number: R727-CL-1110 Start Date*: 2013-04-09
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Atorvastatin versus Ezetimibe Added-on to Atorvastatin versus Atorvastatin Dose Increase versus Switch to Rosuvast...
    Medical condition: Patients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with atorvastatin (20mg or 40mg) with or with...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017479-29 Sponsor Protocol Number: I1V-MC-EIAF Start Date*: 2010-07-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination with Atorvastatin, Simvastatin, and Rosuvastatin in Patients with Hypercholesterolemia or Low HDL-C
    Medical condition: Hypercholesterolemia or Low HDL-C
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020604 Hypercholesterolemia LLT
    12.1 10024915 Low HDL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:21:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA